bcma targeted therapies market analysis, b cell maturation antigen targeted therapies market share, bcma targeted therapies market demand, b cell maturation antigen targeted therapies market forecast, bcma targeted therapies market insights, bcma targeted therapies market research
How much is the b-cell maturation antigen (bcma) targeted therapies market worth, and how is it expected to expand?
The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.21 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth in the historic period can be attributed to growing focus on hematologic malignancies, rising investments in oncology research, growing demand for personalized medicine, increasing adoption of CAR-T cell therapies, and rising healthcare expenditure.
The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $36.66 billion in 2029 at a compound annual growth rate (CAGR) of 24.6%. The growth in the forecast period can be attributed to growing focus on cancer research, shifts toward targeting specific molecular markers, incidence of cancers, surge in biotech investments, and increasing use of cell and gene therapies. Major trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, advancements in the next-generation car-t cell therapies, advances in targeted antibody-drug conjugates, and development of off-the-shelf treatments.
Get Your Free Sample of The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
Which industry factors have accelerated the b-cell maturation antigen (bcma) targeted therapies market’s expansion?
The rising incidence of multiple myeloma is expected to propel the growth of the b-cell maturation antigen (BCMA) targeted therapies market going forward. Multiple myeloma is a type of cancer that primarily affects plasma cells, which are a crucial component of the immune system responsible for producing antibodies. The increasing incidence of multiple myeloma is attributed to several factors, including an aging global population, improved diagnostic capabilities, and variations in healthcare access. B-cell maturation antigen (BCMA) targeted therapies are crucial in treating multiple myeloma by targeting and eliminating malignant plasma cells that express BCMA, offering a promising approach for more effective and targeted treatment. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization, in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 cases in women. Additionally, about 12,540 deaths are anticipated, including 7,020 in men and 5,520 in women. Therefore, the rising incidence of multiple myeloma is driving growth in the b-cell maturation antigen (BCMA) targeted therapies market.
What are the primary segments of the b-cell maturation antigen (bcma) targeted therapies market?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Order your report now for swift delivery
Which firms are leading the b-cell maturation antigen (bcma) targeted therapies market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
Which market trends are set to define the future of the b-cell maturation antigen (bcma) targeted therapies market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing innovative treatments such as CAR-T cell therapy to enhance the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient’s T cells to express chimeric antigen receptors (CARs) to target and kill cancer cells. For instance, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.
Which geographic trends are shaping the b-cell maturation antigen (bcma) targeted therapies market, and which region has the highest market share?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025 Offer?
The b-cell maturation antigen (bcma) targeted therapies market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
B-cell maturation antigen (BCMA) targeted therapies refer to a class of treatments designed to specifically target BCMA, a protein expressed on the surface of mature B-cells and plasma cells. BCMA is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies represent a significant advancement in the treatment of multiple myeloma, offering effective options for patients with relapsed or refractory disease.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
